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included in a logistic regresión, D and Tn remained as the
only independent predictors of outcome. Tn+ lost its pre-
dictive ability in non diabetics (RR = 1.2 against T-; IC
95% = 0.4–3.9; p = 0.77) and increased it in diabetics
(RR = 7.9; IC 95% =1.5–41.0; p = 0.014). In the groups
D-T- and D+T+ the percentage of combinated outcome
were 7.0% and 32.7%, respectively. CONCLUSIONS:
diabetes and Tn are independent predictors of outcome
in the ﬁrst three months after an acute coronary syndrome
without ST segment elevation. Their predictive ability is
additive, so that diabetics with elevated Tn have ﬁve times
the risk of non-diabetics with low Tn. The ability of Tn
to predict major events seems to be lost in non-diabetic
patients.
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OBJECTIVE: The use of cardiac stents is an example of
a technology with both widely discussed cost concerns
and widely adopted use. We examined trends in Medicare
spending overall and for cardiac services from 1995 to
2000 to examine systematic response to the adoption of
this new technology. METHODS: We used all Medicare
hospitalizations from 1995 through 2000. Cases were
identiﬁed for: percutaneous transluminal coronary angio-
plasty (PTCA), stent use, and coronary artery bypass graft
(CABG) surgery. The number of cases, length of stay
(LOS), costs, and total payments were calculated. All
dollar amounts were inﬂated to 2001. RESULTS: Stent
use in PTCA increased from 37% in 1996 to 85% in
2000. The number of PTCAs increased by 91,500 (46%)
from 1995 to 2000 and the number of CABG increased
by 2350 (1.3%). The combined rate for PTCA and CABG
was 12.0 per thousand beneﬁciaries in 2000, an 18.3%
increase since 1995. At $3,000 per case, the cost for stents
was $740 million in 2000. LOS and cost for all PTCAs
decreased from 4.8 days to 3.7 days, and from $14,900
to $13,100. The cost of CABG decreased by $3355 per
case. The cost per beneﬁciary for PTCA and CABG
remained nearly constant and inpatient cardiac care
decreased from $756 per beneﬁciary in 1995 to $698 in
2000. While changes following 1996 cost $1.1 Billion for
stents, other changes in the system saved $6.3 billion.
CONCLUSIONS: While the introduction of stents into
common practice for cardiac care added new costs, com-
pensating changes was induced in the system resulted in
substantial savings. The direct cost of new technologies
is a poor measure of expected system performance. Bal-
anced examination of system costs and clinical perfor-
mance are necessary to avoid irrational fear of short-term
costs at the expense of long-term cost and care 
improvements.
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OBJECTIVE: Cholesterol lowering has been shown 
to reduce cardiovascular morbi-mortality. National and
international (e.g, US NCEP) guidelines have deﬁned
LDL-C treatment initiation levels (TIL) and goals for
patients with different levels of coronary heart disease
(CHD) risk according to the number of CHD risk factors
(CRF) associated to dyslipidemia or to prior CHD. The
objective of this study was to measure the proportions 
of patients above AFSSAPS (French Drug Agency) TIL 
[1CRF > 220mg/dl; 2CRF > 190mg/dl; 3CRFs >
160mg/dl; >3CRFs and prior CHD > 130mg/dl] and
NCEP goal in patients with different CHD risk level and
treated with lipid lowering agents (LLA). METHOD: A
total of 3173 Dyslipidemic patients managed by general
practitioners were randomly selected from a French GPs
computerized database. History of CHD and number of
CRF (age, family history of premature CHD, smoking,
hypertension, HDL-C < 0.9mmol/L, diabetes) were doc-
umented. Percent of patients above AFSSAPS TIL and
NCEP goal was deﬁned for each level of CHD risk.
RESULTS: Twenty-one percent of patients had a history
of CHD. Using AFSSAPS guidelines the distribution of
primary prevention patients according to the number of
CRFs (1, 2, 3, > 3) was 1.6, 25.5, 31.7 and 20.1%, respec-
tively. Almost 40% of CHD patients remained above TIL
and the percentages of primary prevention patients above
TIL varied from 3.9% for patients with 1CRF to 46.5%
for patients with >3CRFs (p < 0.001). Using NCEP guide-
lines, percentage of patients not at goal in the different
CHD risk categories were signiﬁcantly higher and 74.3%
of CHD patients were not at LDL-C treatment goal.
CONCLUSION: Seventy-three percent of patients pre-
scribed LLA were at high CHD risk. Increasing with CHD
risk level, large numbers of patients were above TIL and
LDL-C treatment goal. More effective interventions are
needed in lipid lowering therapy.
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OBJECTIVES: A prospective clinical study was per-
formed to compare the efﬁcacy of low-molecular weight
